Patients with stable coronary artery disease incur substantial healthcare costs that vary by CVD risk profile, with higher-risk patients incurring higher initial but lower lifetime costs due to shorter life expectancy.
No takes yet. Share an insight, caveat, or question.
High-risk stable CAD patients drive greater short-term costs; hypothesis-generating for risk-stratified economic models but should not yet change practice.
Walker et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: